Actively Recruiting
Growth Hormone for the Treatment of Gastroparesis
Led by Mayo Clinic · Updated on 2026-04-16
10
Participants Needed
2
Research Sites
162 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
CONDITIONS
Official Title
Growth Hormone for the Treatment of Gastroparesis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Symptoms lasting more than 6 months that have not responded satisfactorily to standard treatment
- Gastroparesis Cardinal Symptom Index (GCSI) score greater than 21
- Age between 18 and 65 years
You will not qualify if you...
- History of growth hormone deficiency, hypothalamic or pituitary disease
- Diabetes
- Prior use of growth hormone therapy
- Age-adjusted low serum IGF1
- Women on oral estrogen therapy
- Pregnancy or nursing
- History of malignant solid tumors
- Obesity with BMI greater than 30
- History of coronary and thromboembolic diseases
- History of sarcoidosis
- History of pituitary surgery
- History of thyroid nodules
- Any condition that would impede compliance or completion of the study
- Failure to give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Mayo Clinic
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
Actively Recruiting
Research Team
G
Guillermo GI Program Coordinator, Research
CONTACT
T
Tisha Lunsford, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here